Li Lanlan, Xie Saiyang, Deng Wei
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan, China; Department of Endocrinology, Renmin Hospital of Wuhan University, Wuhan, China; Cardiovascular Research Institute of Wuhan University, Wuhan, 430060, China.
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China; Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan, China; Department of Endocrinology, Renmin Hospital of Wuhan University, Wuhan, China; Cardiovascular Research Institute of Wuhan University, Wuhan, 430060, China.
Eur J Pharmacol. 2025 Jan 15;987:177101. doi: 10.1016/j.ejphar.2024.177101. Epub 2024 Nov 27.
Cardiovascular diseases (CVDs) are becoming serious disease that endangering human health due to the increasing morbidity and mortality, and many molecular targets are involved in this complex pathologic process. Recently, RNA-binding proteins (RBPs) have received potential attention as a promising targets for preventing CVDs, including myocardial hypertrophy, dilated cardiomyopathy (DCM), myocardial fibrosis, and pulmonary hypertension (PH). As important regulators of RNA metabolism, RBPs play important roles in all steps of the gene expression cascade,and affect the occurrence and development of various diseases. In this review, we discuss the regulatory role of RBPs on various CVDs at the post transcriptional modification level based on current research. We also highlight the existing and potential RNA-based therapeutics that could impact future CVD treatments.
心血管疾病(CVDs)正成为一种严重危害人类健康的疾病,其发病率和死亡率不断上升,并且许多分子靶点参与了这一复杂的病理过程。最近,RNA结合蛋白(RBPs)作为预防心血管疾病(包括心肌肥大、扩张型心肌病(DCM)、心肌纤维化和肺动脉高压(PH))的有前景的靶点受到了潜在关注。作为RNA代谢的重要调节因子,RBPs在基因表达级联反应的所有步骤中发挥重要作用,并影响各种疾病的发生和发展。在本综述中,我们基于当前研究讨论RBPs在转录后修饰水平对各种心血管疾病的调节作用。我们还强调了现有和潜在的基于RNA的疗法,这些疗法可能会影响未来心血管疾病的治疗。